EFElena Glebovna Filatova

Elena Glebovna Filatova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena Glebovna Filatova has a total of 181 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global practical recommendations from the International Headache Society for the treatment of migraine attacks: an adapted Russian-language version

    by V. V. Osipova, M. A. Vinokurov, A. R. Artemenko, E. R. Lebedeva, A. V. Sergeev, Yu. E. Azimova, A. V. Amelin, L. R. Akhmadeeva, O. B. Doronina, E. V. Ekusheva, et al.

    The article was prepared by experts of the Russian Headache Society (RHS) and represents an adapted Russian-language version of the International Headache Society (IHS) Global practice recommendations for the treatment of migraine attacks, developed taking into account data from systematic reviews, meta-analyses and consensus documents. The recommendations have two levels: optimal – for countries and regions where most medicines are available, and basic – for regions with limited treatment options. Treatment algorithms using non-steroidal anti-inflammatory drugs, triptans, and gepants are presented, along with specific considerations for their use in special patient groups: pregnant women, the elderly, and patients with cardiovascular diseases. Medicines not registered in the Russian Federation and available alternatives are indicated. The adapted recommendations take into account the Russian specifics of drug availability and the clinical recommendations of the Ministry of Health of Russia. Compliance with the recommendations will improve the quality of care for patients with migraine in the Russian Federation.

  • Complications of migraine

    by E. G. Filatova

    Migraine is a common and benign disease that does not shorten the life and does not lead to disability of patients. Migraine complications are extremely rare and in most cases occur in patients suffering from migraine with aura, with the exception of status migrainosus. The International Classification of headaches in 2018 identifies as complications: status migrainosus, persistent aura without infarction, migrainous infarction and migraine aura-triggered seizure; the appendix discusses visual snow and migraine aura status. The article is of an overview nature, which presents diagnostic criteria, features of differential diagnosis, as well as currently available theoretical approaches to migraine complications. Treatment of status migrainosus, clinical features and therapy of persistent aura without infarction, diagnosis and differential diagnosis of migrainous infarction and ischemic stroke of other causes, differential diagnosis of migraine aura status with organic neurological syndromes, as well as clinical features, pathogenesis and comorbidity of «visual snow» described in the article, are important for the clinical practice of neurologists.

  • Chronic migraine: diagnosis and treatment

    by Filatova E.G. Filatova, Moscow Alexander Vein Headache And Autonomic Disorders Clinic

  • Preventive Pharmacological Treatment of Migraine: International Headache Society (IHS) Global Practice Recommendations

    by E. G. Filatova, A. V. Amelin, N. V. Latysheva

    The article presents an adapted translation of the practice recommendations for the preventive treatment of migraine, released in late 2024 by the International Headache Society (IHS). The document contains 16 of the most important practical questions on migraine prevention, the answers to which are obtained from clinical guidelines from different countries, meta-analyses and randomized clinical trials (RCTs).The main objective of these practice recommendations for migraine prevention is to optimize the use of drugs for effective control of frequent and chronic migraine and to improve the quality of medical care for the greatest number of patients in countries with different levels of economic development. In the Russian Federation (RF), both targeted prophylactic drugs (anti-CGRP monoclonal antibodies, gepants), botulinum toxin type A and most classical oral medications are available. Thus, in our country it is possible to offer preventive treatment of migraine of any level, including the optimal one. In the comments to this article, the authors of the Russian version sought to adapt the answers to the most important questions to clinical practice in the Russian Federation.

  • The socio-economic burden of migraine: yesterday and today

    by I. S. Yadgarov, E. G. Filatova

    Migraine is the most frequent and costly type of headache. The analysis of the «cost of the disease» implies an assessment of direct and indirect costs expressed in monetary units. Drastic changes have recently occurred in approaches to the treatment of the disease, in connection with which there are large differences in the structure of the economic burden «yesterday and today». «Yesterday» knowledge about the pathophysiology of migraine was insufficient and various nonspecific agents were used to treat the disease, the antimigrenous effect of which was manifested as an additional one. The relatively low prices of these ineffective drugs for relieving attacks and preventing migraines were accompanied by high indirect costs due to temporary disability of patients, frequent time off from work, decreased labor productivity, family troubles, etc. Therefore, «yesterday»: the indirect costs associated with migraine therapy outweighed the direct costs. «Today» the cost of drugs for the prevention and pathogenetic agents for the relief of migraine attacks has become significantly higher and their costs are the main part of the costs of migraine therapy, However, the effectiveness of new pathogenetic agents for the treatment of migraines helps to reduce indirect costs and improve the quality of life. Awareness of the change in the ratio of direct and indirect costs, as well as the causes of this phenomenon, will increase patient compliance, correctly allocate costs and ultimately save personal and public financial resources.


  • Open Access

    Efficacy and safety of Russian tableted rizatriptan 10 mg in the treatment of migraine attacks in clinical practice

    by E. G. Filatova, N. V. Latysheva, N. B. Kadymova, A. V. Berdnikova

    Triptans are a targeted therapy for acute migraine attacks. They are recommended for the treatment of severe attacks when non-specific analgesics are not effective. Four of the seven known triptans with different efficacy and individual tolerability are registered in the Russian Federation.   Objective: to determine in an open-label non-comparative single center study efficacy and safety of the new Russian generic tableted rizatriptan 10 mg (Relonova) in real-life clinical practice.   Material and methods. Thirty individuals with migraine took part in the study. Patients took rizatriptan to relieve 4 migraine attacks and filled out self-observation diaries and HIT-6 questionnaire before and after therapy.   Results. The study involved 30 patients (26 women and 4 men) with mean age of 38.7 ± 9.3 years. Duration of migraine was 19.6 ± 11.4 years, mean number of days with migraine per month was 9.5 [5.25; 16.75]. Most patients (67 %) suffered from episodic migraine and 33 % from chronic migraine; 6 patients (20 %) had migraine attacks with aura; 20 individuals (67 %) received preventive therapy. After taking Relonova medication, pain relief was observed in 86 % of attacks, and in 45 % of cases pain disappeared completely; after 24 hours, pain relief was observed in 87 % of cases, and in 68 % – absence of attacks. A significant decrease in headache intensity was observed within 30 minutes after taking the first dose; in 34 % of attacks the headache returned. Additional analgesic treatment was required in 39 % of cases. Adverse events were observed in 25 % of attacks and were mild. The majority (63 %) of the participants were able to successfully terminate 3 attacks and were responders.   Conclusion. Relonova is an effective and safe medication for the relief of migraine attacks.

  • Use of erenumab in real clinical practice

    by Berdnikova A.V. Berdnikova, Kadymova N.B. Kadymova, Latysheva N.V. Latysheva, Naprienko M.V. Naprienko, Filatova E.G. Filatova, Moscow Academician A. Vein Clinic Of Headache And Autonomic Disturbances, I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University


  • A comparative assessment of microbiocenosis of saliva and oropharynx in patients with migraine

    by I.L. Naydenova, A.B. Danilov, A.V. Simonova, A.A. Pilipovich, E.G. Filatova

    OBJECTIVE To identify changes in the microbiome of saliva and to compare it with the microbiome of the oropharynx of patients with migraine MATERIAL AND METHODS Sixty patients with migraine (21—56 years old), were examined using a headache diary, MIDAS and VAS. A microbiological examination of saliva and smear from the mucosa of the posterior wall of the oropharynx with evaluation by the method of mass spectrometry of microbial markers (MSMM) with the determination of 57 microorganisms was performed. All patients had comorbid chronic diseases of the gastrointestinal tract and upper respiratory tract (URT), according to anamnestic data and examination by specialists. RESULTS A significant increase in the content of markers of resident (conditionally pathogenic) microorganisms characteristic of chronic diseases of URT (strepto- and staphylococci); markers of transient microorganisms characteristic of intestinal microflora (clostridia, gram-negative rods, anaerobes) that are normally absent; viral markers of cytomegaloviruses and herpes groups; a decrease in the content of fungi were identified in saliva. A comparative analysis of the microbiome of saliva and oropharynx showed: 1) a significant decrease in the concentration of coccal flora Enterococcus spp., Streptococcus mutans, Staphylococcus aureus, anaerobic bacteria Clostridium difficile and Clostridium perfringens in saliva; enterobacteria Helicobacter pylori; gram-negative rods Kingella spp., fungi and Epstein-Barr virus; 2) an increase in salivary concentrations of Staphylococcus epidermidis, anaerobic Clostridium ramosum and Fusobacterium spp./Haemophilus spp. and gram-negative bacilli Porphyromonas spp. CONCLUSION A comparative assessment of the microbiota of a smear from the posterior wall of the oropharynx and saliva using MMSM showed the presence of dysbiosis both in the oropharynx and in the saliva of patients with migraine. However, there were fewer deviations from the norm in saliva, therefore, for diagnostic purposes, a smear from the posterior wall of the oropharynx is more significant as a biomarker for patients with migraine.


  • Pain syndrome features in different forms of external genital endometriosis: a cross-sectional study

    by Pronina V.A. Pronina, Chernukha G.E. Chernukha, Filatova E.G. Filatova, Solopova A.E. Solopova

  • Open Access

    Alternative and complementary treatments for migraine

    by G. R. Tabeeva, E. G. Filatova, A. V. Amelin, V. V. Osipova, A. R. Artemenko, L. R. Akhmadeeva, E. V. Ekusheva, M. I. Koreshkina, E. R. Lebedeva, A. V. Sergeev, et al.

    Migraine is a chronic neurological disorder that is associated with considerable disadaptive effect on patients. Despite the development of pharmacotherapy strategies for migraine, only one third of patients are satisfied with their overall treatment. Many migraine patients turn to complementary and alternative medicine (CAM), which is not usually considered a part of conventional medicine and is not always evidence-based. In practise, however, they are often used to improve the effectiveness of standard therapy or to provide alternative treatment. In addition, in CAM methods, the patient is actively involved in the choice of treatment strategies, and they have good adherence. The basic principles and approaches of CAM are increasingly being introduced into clinical practise. This review discusses the principles of CAM in the treatment of migraine as a holistic approach using lifestyle strategies and selected non-pharmacological treatments that have been shown to be effective and rational.